Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCR-ABL1 T315I
i
Other names:
ABL proto-oncogene 1, ABL, c-ABL, JTK7, p150, ABL1, BCR, BCR Activator Of RhoGEF And GTPase, BCR, RhoGEF And GTPase Activating Protein, Breakpoint Cluster Region Protein, Renal Carcinoma Antigen NY-REN-26, Breakpoint Cluster Region, D22S11, BCR1, BCR/FGFR1 Chimera Protein, FGFR1/BCR Chimera Protein, D22S662, ALL, CML, PHL
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
25
;
613
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
ABL1 expression (1)
BCR expression (1)
ABL1 expression (1)
BCR expression (1)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
asciminib
Sensitive: A1 - Approval
asciminib
Sensitive
:
A1
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
ponatinib
Sensitive: A1 - Approval
ponatinib
Sensitive
:
A1
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
dasatinib
Resistant: A2 - Guideline
dasatinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
bosutinib
Resistant: A2 - Guideline
bosutinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
nilotinib
Resistant: A2 - Guideline
nilotinib
Resistant
:
A2
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
olverembatinib
Sensitive: B - Late Trials
olverembatinib
Sensitive
:
B
olverembatinib
Sensitive: B - Late Trials
olverembatinib
Sensitive
:
B
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: C1 - Off-label
ponatinib
Sensitive
:
C1
ponatinib
Sensitive: C1 - Off-label
ponatinib
Sensitive
:
C1
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
T-lymphocyte cell therapy
Sensitive
:
C3
T-lymphocyte cell therapy
Sensitive: C3 – Early Trials
T-lymphocyte cell therapy
Sensitive
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
imatinib
Resistant: C3 – Early Trials
imatinib
Resistant
:
C3
imatinib
Resistant: C3 – Early Trials
imatinib
Resistant
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
dasatinib + nilotinib
Resistant: C3 – Early Trials
dasatinib + nilotinib
Resistant
:
C3
dasatinib + nilotinib
Resistant: C3 – Early Trials
dasatinib + nilotinib
Resistant
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
PF-114
Sensitive: C3 – Early Trials
PF-114
Sensitive
:
C3
PF-114
Sensitive: C3 – Early Trials
PF-114
Sensitive
:
C3
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
Tyrosine kinase inhibitor
Sensitive
:
C3
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
olverembatinib
Sensitive: C3 – Early Trials
olverembatinib
Sensitive
:
C3
olverembatinib
Sensitive: C3 – Early Trials
olverembatinib
Sensitive
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
TGRX-678
Sensitive: C3 – Early Trials
TGRX-678
Sensitive
:
C3
TGRX-678
Sensitive: C3 – Early Trials
TGRX-678
Sensitive
:
C3
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
axitinib
Sensitive: C4 – Case Studies
axitinib
Sensitive
:
C4
axitinib
Sensitive: C4 – Case Studies
axitinib
Sensitive
:
C4
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
dasatinib + axitinib
Sensitive: C4 – Case Studies
dasatinib + axitinib
Sensitive
:
C4
dasatinib + axitinib
Sensitive: C4 – Case Studies
dasatinib + axitinib
Sensitive
:
C4
BCR-ABL1 T315I
Non-Hodgkin’s Lymphoma
BCR-ABL1 T315I
Non-Hodgkin’s Lymphoma
imatinib
Sensitive: C4 – Case Studies
imatinib
Sensitive
:
C4
imatinib
Sensitive: C4 – Case Studies
imatinib
Sensitive
:
C4
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
NT-157
Sensitive: D – Preclinical
NT-157
Sensitive
:
D
NT-157
Sensitive: D – Preclinical
NT-157
Sensitive
:
D
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
sorafenib
Sensitive: D – Preclinical
sorafenib
Sensitive
:
D
sorafenib
Sensitive: D – Preclinical
sorafenib
Sensitive
:
D
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
CUDC-907
Sensitive: D – Preclinical
CUDC-907
Sensitive
:
D
CUDC-907
Sensitive: D – Preclinical
CUDC-907
Sensitive
:
D
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
ponatinib + GMX1778
Sensitive: D – Preclinical
ponatinib + GMX1778
Sensitive
:
D
ponatinib + GMX1778
Sensitive: D – Preclinical
ponatinib + GMX1778
Sensitive
:
D
BCR-ABL1 T315I
Leukemia
BCR-ABL1 T315I
Leukemia
ponatinib + asciminib
Sensitive: D – Preclinical
ponatinib + asciminib
Sensitive
:
D
ponatinib + asciminib
Sensitive: D – Preclinical
ponatinib + asciminib
Sensitive
:
D
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
IODVA1
Sensitive: D – Preclinical
IODVA1
Sensitive
:
D
IODVA1
Sensitive: D – Preclinical
IODVA1
Sensitive
:
D
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
BCR-ABL1 T315I
Acute Lymphocytic Leukemia
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
venetoclax
Sensitive: D – Preclinical
venetoclax
Sensitive
:
D
BCR-ABL1 T315I
Leukemia
BCR-ABL1 T315I
Leukemia
PD-0325901
Sensitive: D – Preclinical
PD-0325901
Sensitive
:
D
PD-0325901
Sensitive: D – Preclinical
PD-0325901
Sensitive
:
D
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
axitinib + asciminib
Sensitive: D – Preclinical
axitinib + asciminib
Sensitive
:
D
axitinib + asciminib
Sensitive: D – Preclinical
axitinib + asciminib
Sensitive
:
D
BCR-ABL1 T315I
Chronic Myeloid Leukemia
BCR-ABL1 T315I
Chronic Myeloid Leukemia
KF-1601
Sensitive: D – Preclinical
KF-1601
Sensitive
:
D
KF-1601
Sensitive: D – Preclinical
KF-1601
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login